{"id":6863,"date":"2012-01-17T07:11:13","date_gmt":"2012-01-17T06:11:13","guid":{"rendered":"http:\/\/www.ilmelanoma.com\/?p=6863"},"modified":"2026-10-16T10:47:15","modified_gmt":"2026-10-16T09:47:15","slug":"luso-degli-anti-estrogeni-in-donne-affette-da-tumore-al-seno-riduce-il-rischio-di-sviluppare-il-melanoma","status":"publish","type":"post","link":"https:\/\/www.ilmelanoma.com\/en\/luso-degli-anti-estrogeni-in-donne-affette-da-tumore-al-seno-riduce-il-rischio-di-sviluppare-il-melanoma\/","title":{"rendered":"L&#8217;uso degli anti estrogeni in donne affette da tumore al seno riduce il rischio di sviluppare il melanoma"},"content":{"rendered":"<p>Secondo uno studio pubblicato nel\u00a0<em>Cancer Prevention Research l&#8217;uso di supplementi estroprogestinici \u00e8 in grado di ridurre il rischio, nelle donne affette da tumore al seno, di sviluppare un melanoma. Lo studio finanziato dal Swiss Research Foundation against Cancer riporta uno studio su 7360 donne con tumore al seno dal 1980 al 2005 sono state studiate dal Dr Christine Bouchardy dell&#8217;Universit\u00e0 di Ginevra. Lo studio ha dimostrato che il rischio di sviluppare un melanoma era del 60 % pi\u00f9&#8217; elevato tra le donne che non ricevevano terapia antiestrogena<\/em><\/p>\n<p><em><a href=\"https:\/\/cancerpreventionresearch.aacrjournals.org\/content\/5\/1\/82.full?sid=c96a0309-1857-4654-b4ae-96aaa7e34e6c\" target=\"_blank\">Abstract (acquits l&#8217;articolo)<\/a>: Increased risk of secondary\u00a0melanoma\u00a0after breast cancer has been reported. Several lines of evidence suggest that elevated estrogen levels may be implicated in\u00a0melanoma\u00a0etiology. Accordingly, use of antiestrogens should be associated with decreased risk of\u00a0melanoma. We compared\u00a0melanomaincidence among a cohort of breast cancer patients with and without antiestrogen therapy, with data from the Geneva Cancer Registry. The cohort consisted of 7,360 women diagnosed with breast cancer between 1980 and 2005. About 54% of these patients received antiestrogens. All women were followed until December 2008. We compared cutaneous\u00a0melanoma\u00a0incidence rates among patients with and without antiestrogens with those expected in the general population by age and period standardized incidence ratios (SIR). A total of 34 women developed a\u00a0melanoma\u00a0during the follow-up period. Compared with the general population, the risk of\u00a0melanoma\u00a0was higher for patients who did not receive antiestrogens (SIR: 1.60, 95% CI: 1.08\u20132.12,\u00a0<\/em><em>P<\/em> = 0.02). On the contrary, the risk was close to 1 (SIR: 0.98, 95% CI: 0.40\u20131.56,<em>P<\/em> = 0.57) for patients who received antiestrogen therapy. This study suggests that antiestrogen therapy modifies the risk of\u00a0melanoma\u00a0after breast cancer. Although our results are in agreement with the hypothesis that estrogens could play a role in\u00a0melanoma\u00a0occurrence, they need to be replicated in a larger study with data on potential confounders.\u00a0<em>Cancer Prev Res; 5(1); 82\u201388. \u00a92011 AACR<\/em>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Secondo uno studio pubblicato nel\u00a0Cancer Prevention Research l&#8217;uso di supplementi estroprogestinici \u00e8 in grado di ridurre il rischio, nelle donne affette da tumore al seno, di sviluppare un melanoma. Lo studio finanziato dal Swiss Research Foundation against Cancer riporta uno studio su 7360 donne con tumore al seno dal 1980 al 2005 sono state studiate [&hellip;]<\/p>\n","protected":false},"author":13,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[778],"tags":[592,593,320],"class_list":["post-6863","post","type-post","status-publish","format-standard","hentry","category-prevenzione-melanoma","tag-ed","tag-estroprogestinici","tag-melanoma"],"_links":{"self":[{"href":"https:\/\/www.ilmelanoma.com\/en\/wp-json\/wp\/v2\/posts\/6863","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ilmelanoma.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ilmelanoma.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ilmelanoma.com\/en\/wp-json\/wp\/v2\/users\/13"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ilmelanoma.com\/en\/wp-json\/wp\/v2\/comments?post=6863"}],"version-history":[{"count":1,"href":"https:\/\/www.ilmelanoma.com\/en\/wp-json\/wp\/v2\/posts\/6863\/revisions"}],"predecessor-version":[{"id":10830,"href":"https:\/\/www.ilmelanoma.com\/en\/wp-json\/wp\/v2\/posts\/6863\/revisions\/10830"}],"wp:attachment":[{"href":"https:\/\/www.ilmelanoma.com\/en\/wp-json\/wp\/v2\/media?parent=6863"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ilmelanoma.com\/en\/wp-json\/wp\/v2\/categories?post=6863"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ilmelanoma.com\/en\/wp-json\/wp\/v2\/tags?post=6863"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}